Using Multiobjective Optimization and Energy Minimization to Design an Isoform-Selective Ligand of the 14-3-3 Protein

  • Hernando Sanchez-Faddeev
  • Michael T. M. Emmerich
  • Fons J. Verbeek
  • Andrew H. Henry
  • Simon Grimshaw
  • Herman P. Spaink
  • Herman W. van Vlijmen
  • Andreas Bender
Part of the Lecture Notes in Computer Science book series (LNCS, volume 7610)

Abstract

Computer simulation techniques are being used extensively in the pharmaceutical field to model protein-ligand and protein-protein interactions; however, few procedures have been established yet for the design of ligands from scratch (‘de novo’). To improve upon the current state, in this work the problem of finding a peptide ligand was formulated as a bi-objective optimization problem and a state-of-the-art algorithm for evolutionary multiobjective optimization, namely SMS-EMOA, has been employed for exploring the search space. This algorithm is tailored to this problem class and used to produce a Pareto front in high-dimensional space, here consisting of 2322 or about 1030 possible solutions. From the knee point of the Pareto front we were able to select a ligand with preferential binding to the gamma versus the epsilon isoform of the Danio rerio (zebrafish) 14-3-3 protein. Despite the high-dimensional space the optimization algorithm is able to identify a 22-mer peptide ligand with a predicted difference in binding energy of 291 kcal/mol between the isoforms, showing that multiobjective optimization can be successfully employed in selective ligand design.

Keywords

protein design ligand design de novo assembly SMS-EMOA multiobjective optimization 14-3-3 Pareto front multiobjective selection hypervolume indicator 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bates, M.: The Origin of Species - by Means of Natural-Selection or the Preservation of Favored Races in the Struggle for Life - Darwin, C. American Anthropologist 61, 176–177 (1959)CrossRefGoogle Scholar
  2. 2.
    Back, T., Fogel, D.B., Michalewicz, Z.: Handbook of Evolutionary Computation. IOP Publishing Ltd. (1997)Google Scholar
  3. 3.
    Bender, A., Scheiber, J., Bender, A., Glick, M., Davies, J.W., et al.: Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure. Chemmedchem 2, 861–873 (2007)CrossRefGoogle Scholar
  4. 4.
    Macchiarulo, A., Nobeli, I., Thornton, J.M.: Ligand selectivity and competition between enzymes in silico. Nature Biotechnology 22, 1039–1045 (2004)CrossRefGoogle Scholar
  5. 5.
    Kalyanmoy, D.: Multi-Objective Optimization using Evolutionary Algorithms (2001)Google Scholar
  6. 6.
    van der Horst, E., Peironcely, J.E., IJzerman, A.P., Beukers, M.W., Lane, J.R., et al.: A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization. Bmc Bioinformatics 11 (2010)Google Scholar
  7. 7.
    Bender, A., Spring, D.R., Galloway, W.R.J.D., Overington, J.P., van Westen, G.J.P., et al.: Chemogenomics Approaches for Receptor Deorphanization and Extensions of the Chemogenomics Concept to Phenotypic Space. Current Topics in Medicinal Chemistry (2010)Google Scholar
  8. 8.
    van Westen, G.J.P., Wegner, J.K., IJzerman, A.P., van Vlijmen, H.W.T., Bender, A.: Proteochemometric Modeling as a Tool for Designing Selective Compounds and Extrapolating to Novel Targets (2010)Google Scholar
  9. 9.
    Fu, H.A., Subramanian, R.R., Masters, S.C.: 14-3-3 proteins: Structure, function, and regulation. Annual Review of Pharmacology and Toxicology 40, 617–647 (2000)CrossRefGoogle Scholar
  10. 10.
    Wilker, E., Yaffe, M.B.: 14-3-3 Proteins - a focus on cancer and human disease. Journal of Molecular and Cellular Cardiology 37, 633–642 (2004)CrossRefGoogle Scholar
  11. 11.
    Dong, S., Kang, S., Lonial, S., Khoury, H.J., Viallet, J., et al.: Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070. Leukemia 22, 572–577 (2008)CrossRefGoogle Scholar
  12. 12.
    Jayaratnam, S., Khoo, A.K., Basic, D.: Rapidly progressive Alzheimer’s disease and elevated 14-3-3 proteins in cerebrospinal fluid. Age Ageing 37, 467–469 (2008)CrossRefGoogle Scholar
  13. 13.
    Besser, J., Bagowski, C.P., Salas-Vidal, E., van Hemert, M.J., Bussmann, J., et al.: Expression analysis of the family of 14-3-3 proteins in zebrafish development. Gene. Expr. Patterns 7, 511–520 (2007)CrossRefGoogle Scholar
  14. 14.
    Yang, X., Lee, W.H., Sobott, F., Papagrigoriou, E., Robinson, C.V., et al.: Structural basis for protein-protein interactions in the 14-3-3 protein family. Proc. Natl. Acad. Sci. U S A 103, 17237–17242 (2006)CrossRefGoogle Scholar
  15. 15.
    Audie, J., Boyd, C.: The Synergistic Use of Computation, Chemistry and Biology to Discover Novel Peptide-Based Drugs: The Time is Right. Current Pharmaceutical Design 16, 567–582 (2010)CrossRefGoogle Scholar
  16. 16.
    Belda, I., Madurga, S., Llora, X., Martinell, M., Tarrago, T., et al.: ENPDA: an evolutionary structure-based de novo peptide design algorithm. Journal of Computer-Aided Molecular Design 19, 585–601 (2005)CrossRefGoogle Scholar
  17. 17.
    Abe, K., Kobayashi, N., Sode, K., Ikebukuro, K.: Peptide ligand screening of alpha-synuclein aggregation modulators by in silico panning. Bmc Bioinformatics 8 (2007)Google Scholar
  18. 18.
    Zahed, M., Suzuki, T., Suganami, A., Sugiyama, H., Harada, K., et al.: Screening of SMG7-Binding Peptides by Combination of Phage Display and Docking Simulation Analysis. Protein and Peptide Letters 16, 301–305 (2009)CrossRefGoogle Scholar
  19. 19.
    Gillet, V.J.: Applications of evolutionary computation in drug design. Applications of Evolutionary Computation in Chemistry 110, 133–152 (2004)CrossRefGoogle Scholar
  20. 20.
    Nicolaou, C.A., Apostolakis, J., Pattichis, C.S.: De Novo Drug Design Using Multiobjective Evolutionary Graphs. Journal of Chemical Information and Modeling 49, 295–307 (2009)CrossRefGoogle Scholar
  21. 21.
    Keijzer, M.: Genetic and evolutionary computation conference: GECCO 2006, vol. 2. Association for Computing Machinery, New York (2006)Google Scholar
  22. 22.
    Malard, J.M., Heredia-Langner, A., Cannon, W.R., Mooney, R., Baxter, D.J.: Peptide identification via constrained multi-objective optimization: Pareto-based genetic algorithms. Concurrency and Computation-Practice & Experience 17, 1687–1704 (2005)CrossRefGoogle Scholar
  23. 23.
    Yagi, Y., Terada, K., Noma, T., Ikebukuro, K., Sode, K.: In: silico panning for a non-competitive peptide inhibitor. Bmc Bioinformatics 8 (2007)Google Scholar
  24. 24.
    Fjell, C.D., Jenssen, H., Cheung, W.A., Hancock, R.E., Cherkasov, A.: Optimization of Antibacterial Peptides by Genetic Algorithms and Cheminformatics. Chem. Biol. Drug. Des. (2010)Google Scholar
  25. 25.
    Li, C., Pazgier, M., Li, C.Q., Yuan, W.R., Liu, M., et al.: Systematic Mutational Analysis of Peptide Inhibition of the p53-MDM2/MDMX Interactions. Journal of Molecular Biology 398, 200–213 (2010)CrossRefGoogle Scholar
  26. 26.
    Satoh, J., Yamamura, T., Arima, K.: The 14-3-3 protein epsilon isoform expressed in reactive astrocytes in demyelinating lesions of multiple sclerosis binds to vimentin and glial fibrillary acidic protein in cultured human astrocytes. American Journal of Pathology 165, 577–592 (2004)CrossRefGoogle Scholar
  27. 27.
    Roberts, M.R., de Bruxelles, G.L.: Plant 14-3-3 protein families: evidence for isoform-specific functions? Biochemical Society Transactions 30, 373–378 (2002)CrossRefGoogle Scholar
  28. 28.
    Beume, N., Naujoks, B., Emmerich, M.: SMS-EMOA: Multiobjective selection based on dominated hypervolume. European Journal of Operational Research 181, 1653–1669 (2007)MATHCrossRefGoogle Scholar
  29. 29.
    Emmerich, M., Li, B.V.Y., Bender, A., Sanchez-Faddiev, H., Kruisselbrink, J., et al.: Analyzing molecular landscapes using random walks and information theory. Chemestry Central (2009)Google Scholar
  30. 30.
    Kruisselbrink, J.W., Aleman, A., Emmerich, T.M., IJzerman, A., Bender, A., et al.: Enhancing search space diversity in multi-objective evolutionary drug molecule design using niching. In: Proceedings of the 11th Annual Conference on Genetic and Evolutionary Computation, pp. 217–224. ACM, Montreal (2009)CrossRefGoogle Scholar
  31. 31.
    Handl, J., Kell, D.B., Knowles, J.: Multiobjective optimization in bioinformatics and computational biology. IEEE-ACM Transactions on Computational Biology and Bioinformatics 4, 279–292 (2007)CrossRefGoogle Scholar
  32. 32.
    Paul, A.L., Sehnke, P.C., Ferl, R.J.: Isoform-specific subcellular localization among 14-3-3 proteins in Arabidopsis seems to be driven by client interactions. Molecular Biology of the Cell 16, 1735–1743 (2005)CrossRefGoogle Scholar
  33. 33.
    Emmerich, M., Beume, N., Naujoks, B.: An EMO Algorithm Using the Hypervolume Measure as Selection Criterion. In: Coello Coello, C.A., Hernández Aguirre, A., Zitzler, E. (eds.) EMO 2005. LNCS, vol. 3410, pp. 62–76. Springer, Heidelberg (2005)CrossRefGoogle Scholar
  34. 34.
    Vilar, S., Cozza, G., Moro, S.: Medicinal Chemistry and the Molecular Operating Environment (MOE): Application of QSAR and Molecular Docking to Drug Discovery. Current Topics in Medicinal Chemistry 8, 1555–1572 (2008)CrossRefGoogle Scholar
  35. 35.
    Vassilev, V.K., Fogarty, T.C., Miller, J.F.: Information Characteristics and the Structure of Landscapes. Evolutionary Computation (2000)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Hernando Sanchez-Faddeev
    • 1
  • Michael T. M. Emmerich
    • 1
  • Fons J. Verbeek
    • 1
  • Andrew H. Henry
    • 2
  • Simon Grimshaw
    • 2
  • Herman P. Spaink
    • 3
  • Herman W. van Vlijmen
    • 4
  • Andreas Bender
    • 4
  1. 1.Leiden Institute of Advanced Computer ScienceLeiden UniversityLeidenThe Netherlands
  2. 2.Chemical Computing GroupSt John’s Innovation CentreCambridgeUnited Kingdom
  3. 3.Institute of BiologyLeiden UniversityLeidenThe Netherlands
  4. 4.Medicinal Chemistry Division, Leiden / Amsterdam Center for Drug ResearchLeiden UniversityLeidenThe Netherlands

Personalised recommendations